Mabion S.A. — Capital/Financing Update 2026

Feb 9, 2026

Report Content TheManagement Board of Mabion S.A. (the "Company") hereby announces that on9 February 2026, it entered into a loan agreement with an unrelatedentity, i.e. ACRX Investments Limited with its registered office inNicosia, Cyprus (the "Lender"), for up to PLN 6 million (the"Agreement").Pursuantto the Agreement, the loan will be made available at the Company'srequest, in whole or in tranches, will bear interest at a fixed annualrate of 9.53% and will be used to improve the Company's financialliquidity and for corporate purposes. The loan will be granted for aperiod of 6 months from the date of its disbursement. The Agreementprovides for the possibility of converting all or part of the loan,together with interest, into shares of the Company at any time at therequest of the Lender. The share price for the conversion will be equalto the market price of the Company's shares, taking into account a 20%discount, or, in the event of a share issue by the Company, will beequal to the share price offered to other investors.Theloan will be secured by a mortgage on the Company's real estate, aregistered pledge on movable property (selected bioreactors and a systemdesigned for cell line development) owned by the Company, and a blankpromissory note together with a promissory note declaration. TheAgreement contains standard provisions regarding the Company'sobligations and the consequences of their breach, such as an increase ininterest rates or making the entire or part of the loan amount usedimmediately due and payable, in the event of, among other things,failure to repay the loan on time. The loan agreement was concludedunder Polish law.